Search

Dry eye is multifactorial, yet some clinicians approach management of it one-dimensionally, relying solely on traditional treatments like artificial tears and prescription meds. Others have long stood beside the belief [...]

Adding an area of expertise can re-energize a practice by making it more profitable and avoiding burnout. These include myopia management, dry eye, neuro and retina--all lucrative and exciting opportunities [...]

There is no way to deny the potential impact of blue light, given the digital era we are in. To put this into perspective, there are approximately 340 million Americans, [...]

As the clinical battle against the growing prevalence of dry eye continues, the industry has responded with new products and novel approaches to address this debilitating condition afflicting millions of [...]

Artificial intelligence is the current buzzword in all walks of life, but few know that it was first coined in 1956! It has taken time for technology to catch up [...]

Oncology has seen tremendous advancements in a few short years, including multiple FDA approvals in a rapidly expanding class of targeted therapies known as antibody-drug conjugates, or ADCs. These cancer-targeting [...]

The world of retina care continues to move at a rapid rate; staying on top of these advances can enhance our ability to practice fully, provide vision, prevent blindness and [...]

The world of dry eye disease (DED) is exploding, with an estimated 40 million Americans having the condition. (1) The good news--the recent release of new products into the market [...]

Let's dive into both worlds and explore new treatments. Corneal disease has always been a mainstay of optometry, and perhaps the reason we love it is that all the answers [...]

I recently took my daughter to urgent care for an upper respiratory infection and the doctor recommended OTC decongestants; I was miffed. I informed him that I had already tried [...]

The motivation for new diagnostic equipment has changed over the years. When I graduated, a well-known practice management consultant told me to determine how long it would take for reimbursement [...]

The new year is always an incredible opportunity to make a new start; to dream of the potential you want to achieve and then make it happen. The journey and [...]

The article examines the challenge of managing ocular surface disease (OSD) in patients with glaucoma, balancing the need to address dry eye symptoms while minimizing the use of additional medications. Topics discussed include the impact of topical glaucoma medications on the ocular surface, the role of preservative-free and alternative therapies, and strategies for reducing medication burden and improving patient compliance.

The article discusses noteworthy advancements in the treatment of ocular surface disease (OSD). These include the therapies approved by the U.S. Food and Drug Administration (FDA) including those from Tarsus Pharmaceuticals, Bausch + Lomb, and Harrow Health, adjunctive OSD treatments, and allergy treatment advances.

The article critiques the impact of physician benefit managers (PBMs) on rising healthcare costs and the lack of transparency in their operations. Topics discussed include the conflict of interest and opacity of PBMs, the restrictive regulations affecting physician interactions with pharmaceutical companies, and the need for broader reform targeting the true sources of healthcare expenses.

The article discusses new advancements in managing retinal diseases, highlighting treatments like Vabysmo and Eylea High Definition (HD) that reduce injection frequency for wet Age-related Macular Degeneration (AMD), and complement inhibitor drugs for delaying geographic atrophy progression. It highlights the importance of early referral to retina specialists, effective treatment strategies, and the role of optometrists in maintaining patients' visual health through collaborative care.